Compare Stocks: BFRI, ZYBT, ICCC, and TENX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.59	$1.19	$0.55 ▼ $1.61	$23.62M	0.78	571,355 shs	807,575 shs
ICCC ImmuCell	$9.94	$10.58	$4.52 ▼ $12.10	$90.26M	0.54	32,936 shs	5,607 shs
TENX Tenax Therapeutics	$2.13	$10.98	$1.31 ▼ $19.40	$79.71M	0.93	10.60 million shs	2.77 million shs
ZYBT Zhengye Biotechnology	$1.73	$1.44	$0.62 ▼ $13.08	$81.99M	-2.72	4.62 million shs	37,216 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	+7.43%	+35.90%	+66.63%	+79.44%
ICCC ImmuCell	0.00%	-1.19%	-11.33%	+2.79%	+55.31%
TENX Tenax Therapeutics	0.00%	+21.71%	-84.45%	-82.21%	-64.44%
ZYBT Zhengye Biotechnology	0.00%	-15.20%	+30.08%	+112.01%	-81.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.59	$1.19	$0.55 ▼ $1.61	$23.62M	0.78	571,355 shs	807,575 shs
ICCC ImmuCell	$9.94	$10.58	$4.52 ▼ $12.10	$90.26M	0.54	32,936 shs	5,607 shs
TENX Tenax Therapeutics	$2.13	$10.98	$1.31 ▼ $19.40	$79.71M	0.93	10.60 million shs	2.77 million shs
ZYBT Zhengye Biotechnology	$1.73	$1.44	$0.62 ▼ $13.08	$81.99M	-2.72	4.62 million shs	37,216 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	+7.43%	+35.90%	+66.63%	+79.44%
ICCC ImmuCell	0.00%	-1.19%	-11.33%	+2.79%	+55.31%
TENX Tenax Therapeutics	0.00%	+21.71%	-84.45%	-82.21%	-64.44%
ZYBT Zhengye Biotechnology	0.00%	-15.20%	+30.08%	+112.01%	-81.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
ICCC ImmuCell	2.00	Hold	N/A	N/A
TENX Tenax Therapeutics	2.56	Moderate Buy	$14.00	557.28% Upside
ZYBT Zhengye Biotechnology	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BFRI, ZYBT, ICCC, and TENX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
8/11/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	TENX Tenax Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$35.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$40.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $4.00
8/11/2026	TENX Tenax Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$4.00
8/11/2026	TENX Tenax Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$5.00
8/11/2026	TENX Tenax Therapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
8/10/2026	TENX Tenax Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/10/2026	TENX Tenax Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.00
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$46.18M	0.51	N/A	N/A	$0.90 per share	1.77
ICCC ImmuCell	$27.64M	3.27	$0.19 per share	51.56	$2.99 per share	3.32
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$10.42 per share	N/A
ZYBT Zhengye Biotechnology	$116.36M	0.70	N/A	N/A	$0.93 per share	1.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
ICCC ImmuCell	-$1.04M	$0.08	124.27	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-61.54%	-57.42%	11/11/2026 (Estimated)
ZYBT Zhengye Biotechnology	-$9.98M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BFRI, ZYBT, ICCC, and TENX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYBT Zhengye Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
ICCC ImmuCell	0.22	4.75	2.71
TENX Tenax Therapeutics	N/A	15.07	15.07
ZYBT Zhengye Biotechnology	0.03	1.14	0.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
ICCC ImmuCell	13.47%
TENX Tenax Therapeutics	1.67%
ZYBT Zhengye Biotechnology	N/A

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
ICCC ImmuCell	5.70%
TENX Tenax Therapeutics	10.81%
ZYBT Zhengye Biotechnology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	70	14.85 million	13.65 million	No Data
ICCC ImmuCell	70	9.08 million	8.56 million	Not Optionable
TENX Tenax Therapeutics	9	37.42 million	33.38 million	Not Optionable
ZYBT Zhengye Biotechnology	278	47.39 million	N/A	N/A

BFRI, ZYBT, ICCC, and TENX Headlines

Recent News About These Companies

Zhengye Biotechnology Holding Ltd (ZYBT)

August 28 at 9:10 AM | ru.investing.com

Zhengye Biotechnology Regains Nasdaq Minimum Bid Price Compliance

August 6, 2026 | tipranks.com

Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up Today

August 5, 2026 | quiverquant.comQ

Zhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | Benzinga

July 23, 2026 | benzinga.com

Zhengye Biotechnology Addresses Unusual Nasdaq Trading Activity

July 21, 2026 | tipranks.com

Zhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)

July 21, 2026 | msn.com

Zhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading Activity

July 21, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity

July 21, 2026 | globenewswire.com

Why Zhengye Biotechnology Holding Limited (ZYBT) Stock Is Up Today

July 20, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Ltd. Class A

July 13, 2026 | cnn.com

Zhengye Biotechnology Faces Nasdaq Minimum Bid Price Deficiency After May 29 Notice

June 4, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

June 4, 2026 | globenewswire.com

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results

April 28, 2026 | prnewswire.com

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026

April 6, 2026 | quiverquant.comQ

Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure

April 6, 2026 | globenewswire.com

Zhengye Biotechnology Holding Ltd ZYBT

March 28, 2026 | morningstar.comM

Zhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGM

March 25, 2026 | tipranks.com

Zhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGM

February 23, 2026 | tipranks.com

Zhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to Shareholders

February 11, 2026 | markets.businessinsider.com

Zhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder Letter

February 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ZYBT, ICCC, and TENX Company Descriptions

Biofrontera NASDAQ:BFRI

$1.59 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.60 +0.01 (+0.94%)

As of 05:27 AM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

ImmuCell NASDAQ:ICCC

$9.94 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$9.90 -0.04 (-0.38%)

As of 04:11 AM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Tenax Therapeutics NASDAQ:TENX

$2.13 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.21 +0.08 (+3.71%)

As of 05:53 AM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Zhengye Biotechnology NASDAQ:ZYBT

$1.73 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.76 +0.03 (+1.73%)

As of 05:52 AM Eastern

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, ZYBT, ICCC, and TENX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, ZYBT, ICCC, and TENX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, ZYBT, ICCC, and TENX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ZYBT, ICCC, and TENX Company Descriptions

Biofrontera NASDAQ:BFRI

ImmuCell NASDAQ:ICCC

Tenax Therapeutics NASDAQ:TENX

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, ZYBT, ICCC, and TENX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, ZYBT, ICCC, and TENX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, ZYBT, ICCC, and TENX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, ZYBT, ICCC, and TENX Company Descriptions

Biofrontera NASDAQ:BFRI

ImmuCell NASDAQ:ICCC

Tenax Therapeutics NASDAQ:TENX

Zhengye Biotechnology NASDAQ:ZYBT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools